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It has been observed that susceptibility to many degenerative diseases increases concurrently
with industrialization and rising living standards. Although epidemiologic studies suggest that
specific environmental and dietary factors may be important, caloric intake alone (as reflected in
body size) may account for much of the differential risk observed among diverse human
populations. It has been suggested from animal studies that caloric intake may be the primary
effector for many hormonal, metabolic, physiologic, and behavioral responses that coordinate
reproductive strategy to apparent availability of food. When caloric intake is excessive, particularly
at critical developmental stages, physiologic priorities are set for body growth and fecundity rather
than for endurance and longevity. The converse occurs during periods of famine, thus increasing
the probability that sufficient individuals survive to restore the population when conditions
improve. Calorically restricted rodents have significantly longer reproductive and total life spans
than their ad libitum-fed controls and exhibit a spectrum of biochemical and physiologic
alterations that characterize their adaptation to reduced caloric intake. These include reduced
stature, hypercorticism in the absence of elevated adrenocorticotropic hormone levels, increased
metabolic efficiency, decreased mitogenic response coupled with increased rates of apoptosis,
reduced inflammatory response, induction of stress proteins and DNA repair enzymes, altered
drug-metabolizing enzyme expression, and modified cell-mediated immune function. The overall
profile of these changes is one of improved defense against environmental stress. This has been
suggested as the mechanistic basis for the protective effects of low body weight on radiation-
and chemically induced cancers in experimental animals. It may also explain the significantly
higher thresholds of acute toxicity observed when calorically restricted rodents are exposed to
certain test compounds. Environ Health Perspect 106(Suppl 1):313-324 (1998).
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Introduction
Cancer and life span are complex end association between high caloric intake and
points, appearing as a consequence of a the diseases ofaging. This paper describes
chain of molecular events (1-3). Actions new insights into the underlying mecha-
or agents that accelerate this progression nisms by which caloric intake may influ-
of events are candidate risk factors for ence degenerative disease progression and
chronic disease, though precise mecha- reviews the evidence for calorie-dependent
nism(s) remain poorly understood. Both disease susceptibility in humans.
epidemiologic studies (4,5) and laboratory The dose-response relationship between
based animal research (6) now support an caloric intake and life span is not simple. In
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rodent models, for example, animals are at
an increased risk ofdying from protein-calo-
rie malnutrition ifdietary intake is extremely
low. Interestingly, among survivors, caloric
restriction is associated with a significant
reduction in cancer incidence compared to
that in adlibitum-fed controls. With moder-
ate caloric restriction an optimal range may
be found that generally supports reproduc-
tion, disease resistance, and longevity. The
highest levels of caloric intake enhance
growth and reproductive capacity but also
significantly increase risk ofmorbidity, pri-
marily because ofdevelopment ofspecific
cancers (7). These effects are reflected in the
relationship between body weight and mor-
tality, which is essentiallyJ-shaped in rodent
models (8,9) and the human population
(10-13).
Under the usual experimental paradigms,
calorically restricted animals receive a bal-
anced reduction ofthe protein, carbohy-
drate, and fat content ofthe diet without a
reduction ofmicronutrient content. Within
a defined range ofcaloric restriction (typi-
cally 30-50% ofad libitum consumption),
they show a decrease in the incidence and
proliferative rate ofspontaneous and chem-
ically induced neoplasia. They also demon-
strate a significant increase in maximum
achievable life span compared to ad
libitum-fed controls (6,14). Many bio-
chemical and physiologic changes occur
coincident with these effects but are
difficult to distinguish from age-related
pathologies (15). Therefore, for a mecha-
nistic understanding, it is important to char-
acterize and distinguish between the
immediate adaptive response to reduced
caloric intake and the resultant long-term
effects on pathologic end points (7).
Hypercorticism-
an Adaptive Response
to Nutrient Stress
The mechanism controlling the adaptive
response to reduced caloric intake may
involve the complex dynamic interplay
between the hormones that control energy
balance, appetite, cell proliferation and
apoptosis, stress response, metabolic rate,
inflammation, and repair systems (7,16).
Glucocorticoids and insulin appear to play
reciprocal roles as the major mediators of
energy balance and glucose homeostasis in
mammals (17-19). Serum corticosterone
levels rise in response to hypoglycemia and
increase blood glucose levels by inhibiting
glucose transport into peripheral tissues
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while increasing gluconeogenesis and
glucose output by the liver. In the hypo-
glycemic state corticosterone also stimu-
lates appetite by inducing neuropeptide Y
production in the arcuate nucleus of the
hypothalamus (20) and stimulates lipolysis
in adipose tissue while reducing energy
expenditure in other peripheral tissues by
decreasing thermogenesis and inhibiting
the effects ofmitogenic and excitatory hor-
mones (16,18). Conversely, in the hyper-
glycemic state insulin levels rise and decrease
bleod glucose levels by stimulating glucose
uptake and glycogen synthesis in liver and
muscle and by increasing glucose uptake
and lipogenesis in adipose tissue (17,18).
Insulin also stimulates leptin production in
adipose tissue, which in turn decreases
appetite and increases metabolism and
energy expenditure in peripheral tissues
(21-24). Thus, under normal physiologic
conditions a balanced opposing relation-
ship exists between insulin and corticos-
terone that maintains blood glucose levels
within the normal physiologic range (17).
Nutrient stress such as fasting, starva-
tion, or insulin-induced hypoglycemia
results in elevated glucocorticoid levels, but
unlike classic stress, hypothalamic release
of corticotropin-releasing factor (CRF)
does not appear to play a major role in ini-
tiating the glucocorticoid response (25-27).
Rather, arginine vasopressin (AVP) plays
the major role in the hypothalamus and the
adrenal response to adrenocorticotropic
hormone (ACTH) appears amplified by
pancreatic polypeptide, which is secreted
by the pancreas during periods ofhypo-
glycemic stress (28,29). In addition, adrenal
corticosterone secretion may be increased
further by neural stimulation via the
adrenal medulla (30,31). This results in
elevated corticosterone concentrations in
the absence of elevated ACTH (and by
inference CRF) in both starved (25) and
calorically restricted (27,32) rats. Under
normal physiologic conditions, once the
hypoglycemic crisis has been rectified,
insulin levels will rise and, as suggested by
in vitro experiments (33), may downregu-
late adrenal corticosterone secretion in favor
ofdehydroepiandrosterone (DHEA) secre-
tion. Like insulin, DHEA is generally ana-
bolic in function and reportedlyantagonizes
many of the effects of glucocorticoids
(34-37).
However, during pathologic conditions
such as Cushing's syndrome or prolonged
excessive glucocorticoid therapy, natural
feedback regulation is bypassed and a
pathologic hyperglycemia develops, which
is characterized by concurrent elevated
insulin and glucocorticoid levels. Such
conditions ofhypercorticism concurrent
with hyperinsulinemia, if prolonged,
would be expected to result in pathologic
conditions such as atherosclerosis and
mature-onset diabetes (38). Classic stress
appears to be controlled primarily by the
hypothalamo-pituitary-adrenal axis
(HPA). CRF and AVP secretion from the
hypothalamus increase in response to inter-
leukins or neuropeptides and stimulate
ACTH secretion by the pituitary (39).
Thus, plasma concentrations ofboth CRF
and ACTH are increased in addition to
serum corticosterone levels. CRF decreases
hyperphagia (40) and is pyrogenic and an
inflammatory mediator (41).
Antineoplastic Effects
of Glucocorticoids
The net effects ofhypercorticism resulting
from nutrient stress are, therefore, reduc-
tions ofglucose uptake and energy metabo-
lism in peripheral tissues. This in itselfmay
provide a beneficial effect on aging and car-
cinogenesis by reducing rates ofintracellu-
lar glycoxidation and oxidative damage
from respiratory chain enzymes (42,43).
However, the primary mechanism by which
glucocorticoids impact aging and degenera-
tive disease maybe through their antimitotic
andantiinflammatory functions.
Antimitoticeffect
Growth hormone and glucocorticoids are
mutually antagonistic in their effects on
body growth (44) and wound healing (45),
and some ofthe antimitogenic effects ofglu-
cocorticoids are mediated through changes
in the hypothalamic-pituitary-liver growth
hormone/insulinlike growth factor 1 (IGF-
1) axis. Glucocorticoids disrupt the pulsatile
secretory profiles of growth hormone
(46,47) in rats and decrease hepatic IGF-1
expression (48). They also antagonize the
proliferative effects of epidermal growth
factor (EGF) and platelet-derived growth
factor (PDGF) in various cell culture sys-
tems (49,50) and antagonize the stimula-
tory effects ofluteinizing hormone (LH)
on the adenyl cyclase/cAMP system in
Leydig cells and possibly other endocrine
tissues (51,52). Although high glucocorti-
coid levels can cause atrophy of skeletal
muscle, they stimulate hypertrophy in car-
diac muscle (53). This effect is associated
with alterations in expression of myosin
isoforms and results in the high efficiency
V3 isoform being favored over the low
efficiency V, isoform (53,54). Thus, the
antimitogenic effects ofglucocorticoids
appear to be selective.
Apoptosis recently has been proposed
to play an important role in inhibiting
tumor development by eliminating dam-
aged and genetically transformed cells
from tumor-susceptible tissues (55-60).
Apoptosis is characterized as differing from
tissue necrosis in that only selected cells are
eliminated and the resulting cell debris is
immediately phagocytized by adjacent cells
so that an inflammatory response is not
initiated (61,62). Glucocorticoids induce
apoptosis in lymphatic tissues (56) and
fibroblasts (63) and possibly in mammary
epithelium (61,64). Glucocorticoids may
also selectively mediate the effects oftrans-
forming growth factor beta (TGF-P) in
stimulating apoptosis in preneoplastic
hepatocytes (42,50).
Antiinflammatory efects
When used therapeutically, glucocorticoids
are extremely potent antiinflammatory
agents that interact with practically every
stage of the inflammatory response (65).
Although it was once proposed that physio-
logic levels ofendogenous glucocorticoids
stimulated the inflammatory response as
part ofthe general adaptation to stress (66),
it now appears that their physiologic role
during stress is to protect the organism from
an overstimulated inflammatory response
(65,67). Glucocorticoids achieve this by
inhibiting the production of, or antagoniz-
ing the actions of, inflammatory media-
tors such as prostaglandins, leukotrienes,
interleukins, and atrial natriuretic factor
(7,16,65). It is now generally accepted that
many ofthe antiinflammatory and antimi-
togenic effects ofglucocorticoids are medi-
ated by the glucocorticoid-inducible protein
lipocortin 1 (65,68). Lipocortin 1 (also
known as annexin 1) is a glycosylated 37-
kDa Ca2+-dependent phospholipid-bind-
ing protein that inhibits phospholipase A2,
a key enzyme in the synthesis ofinflamma-
tory prostaglandins and leukotrienes from
arachidonic acid (65). In addition to
directly inhibiting phospholipase A2 activ-
ity, lipocortin 1 recently has been shown to
inhibit the EGF-mediated phosphorylation
ofthe cytosolic form ofthis enzyme (phos-
pholipase C [PLAc]) (69,70). PLAc is acti-
vated by phosphorylation as part of a
G-protein-dependent, EGF-mediated mito-
genic response (69). Lipocortin 1 also
mediates glucocorticoid feedback effects on
the HPA axis by inhibiting both basal and
interleukin-induced release of CRF and
AVP by the hypothalamus (39,68,71).
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Glucocorticoids also downregulate mRNA
expression of several key inflammatory
enzymes. These include 12-lipoxygenase
(72) and the inducible but not constitutive
forms ofprostaglandin synthase, cyclooxy-
genase isoform 2 (COX-2) (73-76), nitric
oxide synthase (NOSi) (76-78), and intesti-
nal phospholipase A2 (79). These enzymes
generally are induced by endotoxins, tumor
necrosis factor, interleukins, phorbol esters,
or growth factors. Although it is not known
whether glucocorticoids directly or indi-
rectly repress transcription ofthese enzymes,
lipocortin 1 appears to mediate glucocorti-
coid-mediated downregulation ofNOS;
(80) but not COX-2 (81).
Lipocortin 1 recently has been proposed
to be a mediator ofglucocorticoid-induced
apoptosis. It is induced in apoptotic cells
where it has been proposed to inhibit recog-
nition ofthe dying cells by macrophages
(61). Lipocortin 1 is also a substrate for
transglutaminase, and covalently linked
lipocortin dimers and polymers with other
proteins may be produced in apoptopic
cells (61,82,83). Recently, lipocortin 1 was
shown to protect cultured rat thymocytes
from H202-elicited necrosis. Glucocorticoid
treatment, which induced lipocortin 1,
stimulated apoptosis, whereas treatment
with an antilipocortin 1 antibody enhanced
necrosis (84).
Despite their global antiinflammatory
effects, glucocorticoids have been shown to
potentiate certain aspects ofthe hostdefense
system. For example, they reportedly
induce expression ofboth heat shock pro-
tein 70 (HSP70) (85) and the DNA repair
enzyme 06-methylguarnine-DNA methyl-
transferase (86) in certain tissues. They
also potentiate the effects ofinterleukin-6
and hepatocyte-stimulating factor in
inducing hepatic acute phase proteins such
as Mn-superoxide dismutase and a2-
macroglobulin (87-91). Although both
glucocorticoids and lymphocyte stimula-
tory agents that are mediated via intracellu-
lar Ca2+ or protein kinase C (e.g., calcium
ionophors/phorbol esters, antibodies to
the T-cell antigen receptor) initiate apop-
tosis in maturing lymphocytes, they are
mutually antagonistic to the extent that
glucocorticoids protect lymphocytes from
activation-induced apoptosis (92,93). Thus,
the effects ofglucocorticoids on the inflam-
matory and immune systems are modula-
tory rather than simply suppressive.
Inflammation, necrosis, oxidative
damage, and regenerative hyperplasia all
play significant roles in chemically induced
tumor promotion, and glucocorticoids
have been shown to inhibit hyperplasia and
neoplasia in a number ofsystems. Forexam-
ple, glucocorticoids are used therapeutically
as antineoplastic agents in treating several
types ofleukemia and lymphoma (36,94)
and suppress growth of certain lung or
mammary adenocarcinomas (64,95-97).
Dexamethasone inhibits both peroxisome-
proliferator-induced and lead-nitrate-
induced proliferative hyperplasia in rat
liver (98,99). Glucocorticoids also induce
connexin expression and stimulate gap
junction formation in cultured hepato-
cytes and embryonic cells (100-102).
Inflammatory agents such as phorbol esters
promote, and glucocorticoids inhibit,
papilloma formation in mouse skin (103).
Toxic Effects
ofGlucocorticoids
Chronic and excessive elevation of
glucocorticoid levels increases the risk of
developing hypertension, hyperkalemia, dia-
betes, atherosclerosis, osteoporosis, glau-
coma, and impairment ofthe immune and
reproductive systems (104,105). The
organ most susceptible to glucocorticoid
toxicity appears to be the hippocampus.
High doses ofcorticosterone administered
to adrenalectomized rats resulted in neu-
ronal atrophy in the hippocampus but not
in other areas ofthe brain (38,106,107).
Because the hippocampus, in conjunction
with the hypothalamus, controls feedback
regulation ofthe HPA, it was suggested by
Sapolsky and co-workers (107) that gluco-
corticoid-evoked hippocampal damage
impairs the feedback regulation ofadrenal
glucocorticoid output, which could result
in further increases in glucocorticoid levels
and additional hippocampal damage. This
concept has become known as the gluco-
corticoid cascade hypothesis. Over a life-
time such an effect may result in premature
aging of the brain. Evidence supporting
this hypothesis includes in vitro studies
that have demonstrated that glucocorti-
coids impair the ability of cultured hip-
pocampal cells to withstand neurotoxic
stresses (107). The proposed mechanisms
responsible for these effects include inhibi-
tion ofglucose transport and disruption of
Ca2+ homeostasis (107-109). In humans,
patients with Cushing's syndrome can
exhibit memory impairment that corre-
lated with serum cortisol levels (110), and
dexamethasone treatment has also been
shown to impair declarative memory
performance (111). However, although
hypercorticism often is manifested in
Alzheimer's patients (108), long-term
treatment with glucocorticoids is associated
with delay in the onset ofAlzheimer's
disease (112). Lipocortin 1 is expressed
throughout the brain including the hip-
pocampus and has been shown to protect
against neuronal damage resulting from
either ischemia or N-methyl-D-aspartate
agonists (113,114).
Exposing adult rats to stress, hypercorti-
cism, or glucocorticoid therapy reduces
reproductive hormone levels in both sexes
(7). In males, for example, glucocorticoids
appear to inhibit LH-mediated testosterone
synthesis by cultured rat Leydig cells (115)
and dexamethasone treatment decreases
(whereas adrenalectomy increases) serum
testosterone levels in vivo (116,117). In
females, glucocorticoids decrease follicle-
stimulating hormone (FSH)-stimulated aro-
matase activity and estrogen production by
ovarian granulosa cells (118), suppress ovu-
lation, and inhibit ovarian prostaglandin
metabolism (119). Theyalso inhibit the pre-
ovulatory pituitary LH surge in female rats
(120) and estradiol- and gonadotropin-
releasing hormone-induced LH production
in cultured rat pituitary cells (121). In male
rats glucocorticoids inhibit pituitary secre-
tion ofprolactin (122) but not mean LH
levels (123). However, CRF and stress
inhibit pituitary LH secretion in both sexes
(124,125).
Glucocorticoid-mediated
Effects ofCaloric Restriction
Caloric restriction not only evokes anti-
inflammatory and antineoplastic effects
consistent with chronic hypercorticism but
also protects aging rodents against insulin-
resistant diabetes (126-129), impaired tis-
sue growth and regeneration (130,131),
certain neurologic impairments (132,133),
and reproductive senescence (134,135)
(Table 1). Although these latter effects
appear initially to be inconsistent with
hypercorticism, on further analysis they
appear to be the natural consequence ofthe
nutrient stress produced by caloric restric-
tion under the conditions used for most
experimental paradigms (7).
Several factors differentiate the nutrient
stress produced by caloric restriction from
other stress situations or glucocorticoid
therapy (7). First, unlike treatment with
pharmacologic doses ofsynthetic glucocor-
ticoids, hypercorticism resulting from
nutrient stress involves the natural gluco-
corticoids corticosterone or cortisol. The
effects ofthese natural glucocorticoids are
mediated by serum transcortin and 11p-
hydroxysteroid dehydrogenase, which may
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Table 1. Major effects of caloric restriction.a
Direct effectsb Aging-dependent effectsc
Blood glucose, unchanged or decreased
Pancreas, insulin secretion, decreased
Serum corticosterone, increasedd
Plasma ACTH, decreasedd
Bodytemperature, decreasedd
Hepatic gluconeogenic enzymes, increasedd
Cardiac muscle, myosinV,, decreased; myosin V3, increasedd
Pulsatile growth.hormone, inhibitedd
Hepatic IGF-1 synthesis, decreasedd
Hepatic sex-specific drug metabolism, decreasedd
CelLproliferation, decreasedd
Apoptosis, increasedd
Blood, leukopeniad
Inflammatory response, decreasedd
Lipocortin production, increasedd
12-Lipoxygenase, decreasedd
Male gonadal steroids, feminizedd
Reproductive function, decreasedd
HSP70, increasedd
Neoplasia, delayed
Nephropathy, delayed
Cardiopathy, delayed
Hyperinsulinemia, decreased
Cognitive defects, decreased
Reproductive senescence, delayed
Antioxidant enzymes, increased
DNA repair, increasedd
Pulsatile growth hormone, maintained
Hepatic IGF-1 synthesis, increased
Hepatic sex-specific drug metabolism, increased
Cell proliferation, increased
Blood, leukopeniad
aReferences given in text or in Leakey et al. (7,16) or Hart et al. ( 145). bDirect effects of caloric restriction are
those occurring immediately after restriction is initiated and result directly from the organism's response to caloric
deficit. CAging-dependent effects of caloric restriction are those occurring in response to the delay in physiologic
aging that results from caloric restriction. dEffects that are consistent with hypercorticism.
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protect tissues from extreme hypercorticism
(7). Furthermore, unlike synthetic steroids
such as dexamethasone, corticosterone and
cortisol bind to both Type I and Type II
glucocorticoid receptors, so the Type I
receptor response is not inhibited concur-
rent with an excessive Type II receptor
response (136).
Second, the hypercorticism exhibited by
calorically restricted rodents differs from the
continuously elevated serum corticosterone
levels exhibited by starved or chronically
stressed rodents in that corticosterone levels
are increased above those oftheir adlibiturm-
fed counterparts only during a limited circa-
dian period prior to and coincident with
feeding activity (137). This type ofintermit-
tent hypercorticism appears less damaging
to mitogenic processes than continuously
elevated glucocorticoid levels (7).
Third, because the hypercorticism is a
response to caloric deficit and potential
hypoglycemia and occurs in conjunction
with normal feedback regulatory systems, it
is not associated with chronic hyper-
glycemia or hyperinsulinemia (16,127,138).
Thus, insulin resistance and protein glyca-
tion, which are the usual pathologic conse-
quences of glucocorticoid-induced
hyperglycemia, should not occur. Instead,
rates ofintracellular glycation and oxida-
tion of protein would be expected to
decrease in peripheral tissues because of
reduced glucose incorporation. Reduced
collagen glycoxidation has been observed
in skin from calorically restricted rats
(139), and accumulative oxidative damage
to both protein and DNA is reduced by
caloric restriction in a number of tissues
(43,140-142).
Fourth, under the usual conditions for
caloric restriction experiments, significant
hypercorticism only occurs during the early
stages of restricted feeding (143,144). In
most strains of rodent used in caloric
restriction experiments, body weight gain
is reduced in the restricted animals to an
extent where the body weight difference
between the restricted and ad libitum-fed
animals equals or exceeds the caloric deficit
(Figure 1). Thus, during the latter halfofa
calorically restricted rat's life span, its caloric
consumption per gram body weight is
equal to or greater than that of its ad libi-
tum-fed counterpart. Under these condi-
tions significant hypercorticism would not
be required to protect the animal from
potential hypoglycemia. As a consequence,
during senescence, when rodents are most
susceptible to tissue degeneration because
of reduced capacity for cellular prolifera-
tion and reduced output ofmitogenic hor-
mones (131,146), serum corticosterone
levels normally are no longer significantly
increased in chronically calorically restricted
animals (7,143,144).
The effects of caloric restriction on
biomarkers of mitogenesis are generally
consistent with the occurrence ofhypercor-
ticism during the early but not the late
stages ofcaloric restriction. For example,
caloric restriction from 16 weeks of age
Figure 1. Influence of bodyweight on caloric consump-
tion in calorically restricted Fischer 344 rats. Male
F344 rats housed in a specific pathogen-free barrier
facility at the National Center for Toxicological
Research (Jefferson, AR) were placed on a vitamin-for-
tified NIH-31 diet at 40% of ad libitum food consump-
tion, as described by Duffy et al. ( 147). (A) Body
relative weight curves. (B) Relative food consumption
(expressed as food consumed per gram bodyweight by
the calorically restricted rats as a percentage of that
consumed per gram body weight by the ad libitum-fed
rats) as a function of age. By 50 weeks of age the
calorically restricted rats consume equivalent amounts
of food per gram body weight as their ad libitum-fed
counterparts.
abolishes growth hormone pulsatility in
6-month-old male Brown Norway rats, but
pulsatility is restored in older animals
(148). In male rats pulsatile growth hor-
mone controls hepatic expression of both
IGF-1 and sex-specific drug metabolizing
enzymes such as cytochrome P450 2C11
(CYP2C11) (149,150). As expected from
its effects on pulsatile growth hormone,
caloric restriction decreases hepatic expres-
sion of both IGF-1 and CYP2C11 in
young male rats (151,152). However, as
the rats age hepatic IGF-1 and CYP2C1 1
expression decreases in the ad libitum-fed
rats but is maintained by caloric restric-
tion so that in old rats hepatic IGF-1 and
CYP2C11 expression is greater in the calor-
ically restricted animals (151,152). This
age-dependent biphasic effect of caloric
restriction is illustrated in Figure 2 and is a
common feature ofseveral ofthe reported
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Figure 2. Age-dependent effects of caloric restriction. (A) Schematic representation of the effects of caloric
restriction on mitogenic end points and reproductive function. Reduction in the early burst of activity delays the
degradation of these systems in old age. Examples include cell proliferation in kidney tubule cells from B6D2F1
mice, as measured by in vivo labeling with BrdU (BRDU) (131); expression of hepatic CYP2C11 and its dependent
activity, testosterone 16a-hydroxylase in male F344 rats (CYP) ( 152); and expression of hepatic IGF-1 mRNA in
male F344 rats (IGF-1) (151). Caloric restriction decreases these parameters (B) in young rodents but maintains
them (C) in older rodents.
effects of caloric restriction in rodents.
These include cell proliferation rates in
kidney, pancreas, and possibly liver from
B6D2F1 mice (131), serum DHEA levels
in Fischer 344 rats (153), and reproductive
function in both rats and mice.
Effects on female reproductive funct-
ion include delayed puberty (154,155),
inhibition of LH pulsatility concurrent
with hypercorticism (156), inhibition of
ovulation (157), decreased litter size
(158,159), increased lactational diestrus
(160), and reduced milk production (161)
during the initial period of caloric restric-
tion and delayed reproductive senescence
during the latter stage (135,158). In males
the initial effects of caloric restriction
include decreased LH pulsatility (162),
reduced ratios of serum testosterone to
estradiol (163), decreased sperm motility
in rats (164,165), decreased prostrate
weight, testicular sperm density, and fertil-
ity in mice (159). Long-term caloric
restriction reduces testicular hyperplasia
and delays Leydig cell adenoma formation
in old male rats (163,166), whereas
chronic feeding of a high-calorie diet
reduced reproductive performance in old
male CF-1 mice (167).
The antiinflammatory effects ofcaloric
restriction are also generally consistent
with effects resulting from hypercorticism.
For example, caloric restriction reportedly
induces lipocortin 1 immunoreactive pro-
teins in rat liver (16), inhibits carrageenan-
induced inflammation in mice (168),
decreases 12-lipooxygenase activity in rat
liver and testes (7), delays the onset of
autoimmunity in autoimmune-prone mice
(169), and inhibits promotion of mouse
skin papillomas by phorbol esters
(170,171). In the latter case adrenalectomy
reversed the effect of caloric restriction.
Interestingly, caloric restriction both poten-
tiates regenerative hepatocyte proliferation
in partially hepatectomized rats (172) and
reduces cell proliferation while stimulating
apoptosis in preneoplastic liver (173,174).
Such an effect is consistentwith the reported
dual synergistic and antagonistic effects of
glucocorticoids on TGF-3 in neoplastic
and nonneoplastic hepatocytes (7,50).
Although older caloric-restricted mice
exhibited improved cognitive function,
motor performance, and reduced oxidative
damage in the brain (132,133), caloric
restriction did not inhibit hippocampal
aging in rats, although it did not appear to
be overtly detrimental to the hippocampus
(109,175). However, dieting and dietary
restriction reportedly impair cognitive
function in humans (176). Despite poten-
tial endangerment to the hippocampus,
moderate hypercorticism during nutrient
stress would be expected to be beneficial
because the alternative, hypoglycemia in
conjunction with increased inflammatory
activity, would pose a greater threat to the
entire central nervous system.
Taken together, these effects suggest
that caloric restriction in rodents produces
a series of pleiotropic biochemical and
physiologic effects consistent with a hyper-
corticism condition that is more severe in
the early stages ofcaloric restriction than in
the later stages and that occurs without
concurrent hyperglycemia. The overall
effect ofthis condition is to conserve energy
by minimizing metabolism, proliferation,
and nonessential functions in peripheral
tissues. This in turn appears to minimize
damage to the affected tissues so the pro-
gression ofdegenerative or neoplastic lesions
is delayed.
The recent finding that the body weight
of rodents used in cancer bioassays directly
correlates with terminal incidence ofback-
ground tumors (8,177) is also consistent
with effects on growth and cell prolifera-
tion, which play a major role in mediating
the antineoplastic effects of caloric restric-
tion. These body weight-tumor correla-
tions were demonstrated from analysis of
the control animals from cancer bioassays
conducted by the U.S. National Toxicology
Program. In B6C3F1 mice terminal lung
tumor incidence exhibited a positive corre-
lation with body weight at 9 months on
test, whereas terminal liver tumor inci-
dence correlated optimally with body
weight at 12 months on test (8,178). In
Fischer 344 rats terminal pituitary tumor
incidence exhibited a positive correlation
with body weight at 13 months on test,
whereas terminal leukemia incidence
exhibited a positive correlation with body
weight at 14 weeks (179). Interestingly,
caloric restriction initiated at 6 weeks of
age inhibited leukemia to a much greater
extent than restriction initiated at 14 weeks,
whereas pituitary adenoma formation was
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affected equally by both caloric restriction
paradigms (179). This suggests that criti-
cal periods exist when rodents are most
susceptible to subsequent development of
specific cancer end points. This effect can
also be demonstrated for background liver
tumors in B6C3F1 mice (7).
It would appear, therefore, that the rate
ofgrowth during the early adult period of
an organism's life determines its subsequent
susceptibility to neoplastic or degenerative
diseases, and rates ofgrowth in part depend
on glucocorticoid status and caloric intake.
As stated above, glucocorticoids are a major
component ofthe stress and inflammatory
responses, where their primary functions
appear to be: a) to globally reduce energy
consumption so that energy is channeled
to the site oftrauma or inflammation, and
b) to prevent excessive tissue damage due
to overexpression of the inflammatory
response. During severe nutrient stress
hypercorticism allows an organism to con-
serve energy so that it may survive, but in
the process growth and reproductive,
immune, and cognitive functions may be
compromised. However, caloric excess
may be equally detrimental and result in
overstimulated growth, uncontrolled cell
proliferation, autoimmunity, inflammatory
diseases, and neoplasia. Between these two
extremes lies a physiologic window in
which health and longevity are maximized
(Figure 3). Hypercorticism as a hormonal
response to nutrient stress appears common
to most mammalian species and probably
evolved as a mechanism to ensure survival
ofthe species through periods offamine
(180-183). In times ofabundant food sup-
ply, rapid growth and fecundity are favored
over endurance and longevity. Conversely,
when food becomes scarce reproductive
performance and growth are sacrificed in
favor ofextended total and reproductive life
spans, thus increasing the probability that
sufficient individuals will survive to restore
the population when conditions improve.
Over the past 30 years the animal
husbandry conditions used by commercial
breeders and rodent-testing houses have
been significantly modified to favor growth
and fecundity (184,185). This has resulted
in rodent strains that characteristically suf-
fer from caloric excess and exhibit reduced
life expectancy and many ofthe symptoms
listed on the left side of Figure 3. When
used in toxicity studies these animals are
highly sensitive not only to chemically
induced carcinogenesis but also to the acute
effects of toxic chemicals (186). When
used in moderation with these animals,
CO
0
E
0
Obesity
Carcinogenesis
Heartdisease
Inflammatory diseases
Diabetes
Osteoporosis
Muscular atrophy
Immune dysfunction
Reproductive impairment
Cognitive impairment
Optimal physiologic window
Nutrient stress-hypercorticism
Caloric excess Caloric deficit
Figure 3. Relationship between caloric consumption and morbidity/mortality rates. Evidence from epidemiologicI
and mechanistic studies suggests that the relationship between caloric consumption and morbidity/mortality is
essentially J-shaped. High caloric consumption increases the risk of increased body growth, obesity, and associ-
ated pathologies, whereas extreme nutrient stress resulting from fasting, starvation, or excessive caloric restric-
tion may increase the risk oftissue degeneration and associated pathologies.
dietary restriction decreases the incidence of
both spontaneous and chemically induced
carcinogenesis and also reportedly decreases
the acute toxicity of several chemicals
(186,187). Such effects are consistent with
the antiinflammatory and antineoplastic
effects ofhypercorticism because a height-
ened inflammatory response amplifies the
toxicity ofcarcinogens such as carbon tetra-
chloride (188-191). Although moderate
dietary restriction is recommended for
increasing life span and standardizing back-
ground tumor incidence between studies
(192), excessive dietary restriction, whether
a result of reduced food allocation or
anorectic effects ofthe test chemical, should
be avoided in cancer bioassays, as such con-
ditions would render the bioassay insensi-
tive for the detection ofchemically induced
tumors and reduce life expectancy because
ofthe pathologic conditions listed on the
right-hand side ofFigure 3.
Influence of Caloric Intake
on Human Morbidity
and Mortality
Although the effects ofcaloric restriction
on circadian profiles ofserum cortisol have
not been studied in detail, fasting has been
shown to increase serum cortisol levels in
humans while concurrently decreasing
serum insulin, IGF-1, triiodothyronine,
and testosterone levels (193-196). This
suggests that nutrient stress evokes similar
effects in humans as in rodents.
Although the relationship between
body weight and morbidity is readily
apparent in laboratory animals raised from
similar genetic stock under controlled lab-
oratory environments (177,178,197),
establishing similar trends in the human
population is considerably more difficult.
It is now well established that genetic fac-
tors play a significant role in determining
risk for both cancer and coronary heart
disease (198,199) and behavioral factors
such as cigarette smoking and heavy con-
sumption ofalcohol also influence suscep-
tibility to these diseases (199-201).
Nevertheless, when these factors are taken
into consideration, dietary caloric con-
sumption may be one ofthe most impor-
tant risk factors for a spectrum ofhuman
degenerative diseases (4,202), and human
epidemiology studies have established that
increased body weight-or body mass
index (BMI)-is positively correlated to a
number of morbidity/mortality indices.
These include overall mortality in both
men and women (13,203); cardiovascular
disease (10,13,204); breast, renal, and
endometrial cancer in women (205-207);
and colon cancer in men (208). As in ani-
mal studies (8) the relationship between
BMI, weight, and morbidity/mortality
risk is not always linear in human studies;
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J-curve profiles are frequently produced
instead. Whereas some ofthe risk for low-
body-weight individuals can be attributed
to smoking (13), the studies quoted above
used Western populations, which include
relatively few individuals on low-calorie
diets. Including populations from develop-
ing countries would be expected to pro-
duce mortality curves resembling that
shown in Figure 3. Indeed it frequently has
been noted that as caloric consumption rel-
ative to caloric demand increased in devel-
oped countries, disease susceptibilities
changed from those characteristic ofcaloric
deficit to those characteristic of caloric
excess (209).
Relevance ofCaloric
Restriction Studies
to Antiaging and
AnticancerTherapies
Ofthe several interventions proposed as life
extenders, none have been as successful in
experimental animal studies as caloric
restriction. If the mechanisms described
above prove correct, this is to be expected.
For example, although high pharmacologic
doses of antioxidants can be expected to
reduce or eliminate oxidative damage to
intracellular macromolecules from free
radicals such as superoxide, free radicals
themselves play a beneficial role in cell
regulation, apoptosis, and in fighting path-
ogenic bacteria (210,211). Excessive over-
consumption ofpurified antioxidants by
healthy individuals could therefore be
detrimental to health and has in some cases
been shown to be ineffective as cancer pre-
ventive agents (212). Mitogenic hormones
such as somatotropin or the natural ana-
bolic steroid DHEA may be useful to main-
tain tissue mass in elderly patients exhibiting
a genuine deficit in these hormones, but
their abuse in younger individuals could
result in an excessive mitogenic response
and possible insensitivity in later life.
Likewise, although natural glucocorticoids
appear to play a significant role in mediat-
ing the effects ofcaloric restriction, chronic
consumption in the absence of caloric
deficit may result in hyperglycemia and dia-
betes. Moreover, even caloric restriction
may not be beneficial under all circum-
stances. Although a decreased inflammatory
response appears to be beneficial during the
early stages ofthe carcinogenesis process
(103,213), immunodeficiency once car-
cinogenic tumors have developed will facili-
tate metastatic growth (209). As explained
above, in most animal experiments the
caloric deficit and resultant hypercorticism
has subsided before most tumors reach the
metastatic stage. However, ifcaloric restric-
tion is initiated in cancer patients once the
carcinogenic tumors have been established,
the benefits of its antimitogenic effects
may be outweighed by the risk of its
immunosuppressive effects. In such cases,
immunotoxic stress by using bacterial tox-
ins or purified cytokines (214-217) may
prove a more effective therapy because this
type ofstress would be expected to inhibit
mitogenesis while stimulating the inflam-
matory response.
Conclusions
Caloric intake and body weight can
markedly influence mortality and morbid-
ity rates in laboratory animals. As the mech-
anistic basis for the effect ofcaloric intake
on disease processes becomes increasingly
understood, it is becoming apparent that
caloric intake may exert a similar impact on
human mortality and disease. However, it
is also becoming apparent that caloric
restriction or related interventions should
not be applied indiscriminately to all indi-
viduals. Rather, the relative risks and bene-
fits of all such interventions must be
assessed on a case-by-case basis, taking into
consideration the age, nutritional, and
pathologic status ofthe individual subject.
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